The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking

Le, Tuan; Hopkins, Laura; Faught, Wylam; Fung-Kee-Fung, Michael

doi:10.1016/j.ygyno.2007.02.022

Cited by 22 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results on the role of regression of CA-125 are different from the observation of Le et al, 20 which defined the predictive and prognostic value of this marker. The authors of this article adopted as a criterion response to treatment the decrease in serum CA-125 after 3 courses of NAC greater than 50% of the value of the initial.…”

Section: Association Between Survivin Expression and Oscontrasting

confidence: 99%

Survivin Expression as a Prognostic Factor in Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Treated With Neoadjuvant Chemotherapy

Gąsowska-Bodnar

Bodnar²,

et al. 2014

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Section: Association Between Survivin Expression and Oscontrasting

confidence: 99%

Survivin Expression as a Prognostic Factor in Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Treated With Neoadjuvant Chemotherapy

Gąsowska-Bodnar

Bodnar²,

et al. 2014

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Many works also report on the usefulness of this marker in the use of the neoadjuvant chemotherapy on many levels [14,15,18] but there are also authors who question its relevance in the said therapeutic process [19,20]. Of interest are studies carried out by Kang et al [14], who studied 314 women with ovarian cancer and found that the CA 125 can be a very good predictor of selecting a suitable therapeutic option at the start of the treatment of ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer

Chudecka‐Głaz

Cymbaluk‐Płoska

Menkiszak

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

BackgroundThe most important prognostic factor in the ovarian cancer is optimal cytoreduction. The neoadjuvant chemotherapy, an only optional method of treatment in this case and is still the subject of debate. The object of this study was to evaluate the usefulness of markers: CA 125, HE4, YKL-40 and bcl-2 as well as cathepsin L in predicting optimal cytoreduction and response to chemotherapy.MethodsSera were secured preoperatively. The division into groups was performed retrospectively depending on the method of treatment (surgery vs neoadjuvant chemotherapy) as well as on response to chemotherapy (sensitive vs resistant vs refractory). Comparisons were made between groups, and the diagnostic usefulness of tested proteins was examined.ResultsWe found that statistically significant differences between primary operated patients and patients undergoing neoadjuvant chemotherapy were applicable only to the tumour markers (CA125 1206.79 vs 2432.38, p = 0.000191; HE4 78.87 vs 602.45, p = 0.000004; YKL-40 108.13 vs 203.96, p = 0.003991). Cathepsin-L and Bcl-2 were statistically insignificant. The cut-off point values were determined for the CA 125 (345 mIU/ml), HE4 (218.43 pmol/L) and YKL-40 (140.9 ng/ml). The sensitivity, specificity, PPV and NPV were as follows: CA125 (83.3%; 75%; 80.6%; 78.3%), HE4 (86.6%; 91.3%; 92.9%; 84%) and YKL-40 (75%; 83.3%; 84%; 74.1%).ConclusionAmong the tested proteins the HE4 marker appears to be helpful in forecasting of optimal cytoreduction and possibly also of the prediction of response to platinum analogues used in first-line treatment of ovarian cancer.

show abstract

“…The reliability of the response evaluation during chemotherapy for serous EOC may be improved by the assessment of serum human epididymis protein 4 (4). However, Le et al (5) suggested that the CA-125 response to NACT was not significantly predictive of progression-free survival.…”

Section: Introductionmentioning

confidence: 99%

Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma

et al. 2014

View full text Add to dashboard Cite

The aim of the present study was to evaluate tumor stiffness by ultrasound elastography, which has the potential to provide additional information that is useful in predicting the response to neoadjuvant chemotherapy (NACT) in high-grade serous ovarian carcinoma (HGSC) patients. In total, 32 patients with International Federation of Gynecology and Obstetrics stage III and IV epithelial ovarian cancer treated with NACT underwent transvaginal and transabdominal sonography, followed by elastography and finally, by interval cytoreductive surgery. Histopathological analysis revealed 24 (75%) HGSCs. The mean elasticity score was statistically higher for the post-NACT lesions than for the pre-NACT lesions (3.13±0.57 vs. 2.04±0.51, respectively; P<0.001). The median elasticity score for the pre-NACT lesions on the four-point scale was 2, and the score for the post-NACT lesions was 4. Cases of post-NACT with scores of 3 and 4 had a higher optimal cytoreduction rate than cases with scores of 1 and 2 (93.8 vs. 25.0%, respectively; P<0.001). When the post-NACT elasticity scores of 3 and 4 were used for the prediction of optimal cytoreduction, elastography exhibited 88.2% sensitivity, 85.7% specificity, a 93.8% positive predictive value, a 75.0% negative predictive value and 87.5% accuracy. The results of the current study suggested that elastography is a sensitive tool for the evaluation of NACT in patients with HGSC and that it may aid gynecologists in choosing the optimal cytoreduction.

show abstract

The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking

Cited by 22 publications

References 16 publications

Survivin Expression as a Prognostic Factor in Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Treated With Neoadjuvant Chemotherapy

Survivin Expression as a Prognostic Factor in Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Treated With Neoadjuvant Chemotherapy

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer

Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma

Contact Info

Product

Resources

About